Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · May 2011 · 1 min read
In brief
In brief
This Children's Oncology Group study investigated hedgehog pathway activation in pediatric rhabdomyosarcoma and undifferentiated sarcomas by measuring GLI1 and PTCH expression in archived tumor specimens. Results showed significant pathway activity in embryonal RMS and undifferentiated sarcomas but rarely in alveolar RMS, without correlation to specific clinical phenotypes.
Written by the GCMD Library team from the article.
Statements in this article
Aberrant activation of the hedgehog signaling pathway is implicated widely in both pediatric and adult malignancies.
Inactivation of the hedgehog regulator PTCH is responsible for the Gorlin cancer predisposition syndrome.
The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma.
Expression of GLI1 with or without PTCH was detected in substantial subsets of embryonal rhabdomyosarcoma and undifferentiated sarcoma tumors but only rarely in alveolar rhabdomyosarcoma tumors.
Neither PTCH mutations nor activating SMO mutations were detected in embryonal rhabdomyosarcoma tumors with high GLI1 expression.
Microarray analysis demonstrated relative overexpression of downstream hedgehog targets in embryonal rhabdomyosarcoma tumors with high or intermediate GLI1 expression.
Hedgehog pathway activity in embryonal rhabdomyosarcoma tumors did not correlate with a unique clinical phenotype.